Advertisement
DHR vs STE
Which Stock Would AI Choose? Danaher Corporation (DHR) vs. STERIS plc (STE) Stock Comparison
Key Takeaways
- Danaher Corporation (DHR) trades at a 52-week low around $171, down over 20% YTD amid modest core growth in recent quarters, but benefits from a pending $9.9B acquisition of Masimo to bolster diagnostics.
- STERIS plc (STE) hovers near $207, down about 18% YTD, with steady revenue growth from infection prevention services and upcoming Q4 earnings on May 12 expected to show $1.60B revenue.
- Both healthcare firms face recent market pressure, with DHR showing stronger long-term YTD returns in some metrics but higher volatility; STE offers lower P/E (28.89 vs. 33.23) and consistent dividends.
- DHR's diversified biotech/life sciences exposure contrasts STE's focus on sterilization, with recent sentiment influenced by earnings beats and strategic M&A (mergers and acquisitions).
- Relative performance shows both underperforming broader indices recently, but DHR has raised FY2026 EPS guidance slightly.
- Tickeron's AI tools highlight potential in healthcare via trending bots with up to 285% annualized returns in related sectors.
Introduction
Danaher Corporation (DHR) and STERIS plc (STE) are prominent players in the healthcare sector, focusing on life sciences, diagnostics, and infection prevention. This stock comparison analyzes their recent market performance, business drivers, and relative positioning amid ongoing sector challenges like modest growth and acquisition integrations. Traders seeking momentum plays or investors eyeing defensive healthcare exposure—particularly in tools for bioprocessing, sterilization, and medical devices—will find value in understanding their contrasts in scale, valuation, and catalysts. With both stocks near 52-week lows in recent market activity, the analysis highlights opportunities in relative performance and sentiment shifts.
DHR Overview and Recent Performance
Danaher Corporation (DHR), a global science and technology leader, operates in biotechnology, life sciences, and diagnostics segments. It provides instruments, consumables, and services for therapeutics development, disease research, and clinical diagnostics to pharmaceutical firms, hospitals, and labs. Recent market activity has pressured the stock, trading around $171—near its 52-week low of $170.74—after declining over 20% YTD and 12% in the past month. This follows Q1 2026 results with $5.95B revenue (up 3.7% YoY, slight miss) and adjusted EPS of $2.06 (beat estimates), driven by bioprocessing strength but offset by diagnostics softness. Sentiment has been influenced by the February 2026 announcement to acquire Masimo for $9.9B, enhancing patient monitoring, alongside a quarterly dividend hike to $0.40. Core revenue grew modestly at 0.5%, with FY2026 guidance for 3-6% growth and raised EPS midpoint, yet shares hit new lows amid broader healthcare volatility.
STE Overview and Recent Performance
STERIS plc (STE), headquartered in Mentor, Ohio, specializes in infection prevention and procedural products across Healthcare, Applied Sterilization Technologies (AST), and Life Sciences segments. It offers sterilizers, endoscope systems, surgical equipment, and contract services to hospitals, pharma manufacturers, and labs worldwide. The stock, around $207, reflects recent weakness near its 52-week low of $195.14, down about 18% YTD and 7-8% monthly, mirroring sector trends. Prior quarters showed resilience, with Q3 FY2026 revenue up 9% to $1.5B and adjusted EPS at $2.53, fueled by service (11%) and consumables (8%) growth. Upcoming Q4 results on May 12 anticipate $1.60B revenue and $2.89 EPS. Key developments include a dividend increase to $0.63 (20th consecutive year) and board addition of Pierre Boulud, supporting steady sentiment despite price pressure from market conditions.
Trending AI Robots
Tickeron’s Trending AI Robots page features over 25 top-performing AI trading bots curated from a total of 351 bots that trade thousands of tickers across diverse strategies, timeframes, and sectors. These bots, designed for copy trading, target high-growth areas like semiconductors, industrials, space infrastructure, and healthcare-related plays, delivering impressive stats such as annualized returns up to +285%, win rates up to 88%, and profit factors up to 7.12. Examples include a Space Infrastructure bot (5 tickers, 15-min timeframe) at +285% annualized with 72% win rate, and Semiconductor bots (5-6 tickers, 60-min) averaging 70-95% returns with 60%+ win rates. Varying styles—from trend-following to multi-agent TP/SL (take-profit/stop-loss) exits—adapt to current volatility, outperforming benchmarks like the S&P 500. Explore these bots to enhance your trading edge in dynamic markets like healthcare.
Head-to-Head Comparison
Danaher (DHR) boasts a larger scale with $121B market cap versus STE's $20B, offering broader diversification across biotech therapeutics and life sciences tools, while STERIS (STE) concentrates on essential sterilization and infection control with recurring service revenue (e.g., 11% growth). Growth drivers differ: DHR leverages M&A like Masimo for diagnostics expansion amid modest 0.5% core growth; STE shows stronger organic revenue (8-9%) from consumables and AST. Recent momentum favors neither, both down sharply YTD (DHR ~25% in some views, STE ~18%), near lows. Risk factors include DHR's acquisition debt and diagnostics weakness versus STE's FX exposure and tariff sensitivities. Sector-wise, both in healthcare but DHR has more biotech volatility; STE defensive via essentials. Sentiment tilts to STE's lower P/E and dividends, though DHR analysts project 12% EPS growth.
Tickeron AI Verdict
Tickeron’s AI currently favors Danaher Corporation (DHR) due to its larger scale, strategic Masimo acquisition positioning it for diagnostics catalysts, and raised FY2026 EPS guidance amid bioprocessing stability. While both exhibit trend weakness near lows, DHR's diversified exposure and historical outperformance in life sciences offer higher probabilistic upside relative to STE's steady but narrower growth, assuming sector recovery.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DHR is a Hold and STE is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DHR’s FA Score shows that 1 FA rating(s) are green whileSTE’s FA Score has 1 green FA rating(s).
- DHR’s FA Score: 1 green, 4 red.
- STE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DHR’s TA Score shows that 5 TA indicator(s) are bullish while STE’s TA Score has 4 bullish TA indicator(s).
- DHR’s TA Score: 5 bullish, 5 bearish.
- STE’s TA Score: 4 bullish, 4 bearish.
Price Growth
DHR (@Medical Specialties) experienced а -1.61% price change this week, while STE (@Medical/Nursing Services) price change was -1.60% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.45%. For the same industry, the average monthly price growth was +2.48%, and the average quarterly price growth was -3.19%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.52%. For the same industry, the average monthly price growth was -4.27%, and the average quarterly price growth was -16.56%.
Reported Earning Dates
DHR is expected to report earnings on Jul 28, 2026.
STE is expected to report earnings on Aug 10, 2026.
Industries' Descriptions
@Medical Specialties (+0.45% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (-0.52% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| DHR | STE | DHR / STE | |
| Capitalization | 127B | 19.8B | 641% |
| EBITDA | 7.08B | 1.59B | 444% |
| Gain YTD | -21.995 | -19.402 | 113% |
| P/E Ratio | 34.53 | 25.27 | 137% |
| Revenue | 24.8B | 5.94B | 418% |
| Total Cash | 5.7B | N/A | - |
| Total Debt | 18.5B | 2.09B | 886% |
DHR | STE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 81 | 68 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 10 Undervalued | 8 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 84 | |
SMR RATING 1..100 | 80 | 67 | |
PRICE GROWTH RATING 1..100 | 60 | 62 | |
P/E GROWTH RATING 1..100 | 60 | 83 | |
SEASONALITY SCORE 1..100 | 30 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
STE's Valuation (8) in the Medical Specialties industry is in the same range as DHR (10). This means that STE’s stock grew similarly to DHR’s over the last 12 months.
STE's Profit vs Risk Rating (84) in the Medical Specialties industry is in the same range as DHR (100). This means that STE’s stock grew similarly to DHR’s over the last 12 months.
STE's SMR Rating (67) in the Medical Specialties industry is in the same range as DHR (80). This means that STE’s stock grew similarly to DHR’s over the last 12 months.
DHR's Price Growth Rating (60) in the Medical Specialties industry is in the same range as STE (62). This means that DHR’s stock grew similarly to STE’s over the last 12 months.
DHR's P/E Growth Rating (60) in the Medical Specialties industry is in the same range as STE (83). This means that DHR’s stock grew similarly to STE’s over the last 12 months.
| DHR | STE | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 56% | 2 days ago 70% |
| Stochastic ODDS (%) | 2 days ago 56% | 2 days ago 59% |
| Momentum ODDS (%) | 2 days ago 62% | 2 days ago 51% |
| MACD ODDS (%) | 2 days ago 67% | 2 days ago 46% |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 55% |
| TrendMonth ODDS (%) | 2 days ago 54% | 2 days ago 53% |
| Advances ODDS (%) | 8 days ago 54% | 19 days ago 49% |
| Declines ODDS (%) | 6 days ago 60% | 13 days ago 55% |
| BollingerBands ODDS (%) | 2 days ago 65% | 2 days ago 55% |
| Aroon ODDS (%) | 2 days ago 50% | N/A |
Advertisement
DHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To DHR | 1D Price Change % | ||
|---|---|---|---|---|
| DHR | 100% | +0.58% | ||
| TMO - DHR | 77% Closely correlated | -0.13% | ||
| A - DHR | 73% Closely correlated | -0.45% | ||
| RGEN - DHR | 68% Closely correlated | -4.05% | ||
| RVTY - DHR | 64% Loosely correlated | -0.96% | ||
| BIO - DHR | 64% Loosely correlated | -0.47% | ||
More | ||||